We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat
Read MoreHide Full Article
Intellia Therapeutics (NTLA - Free Report) incurred a loss of $1.96 per share for first-quarter 2022, wider than the year-ago loss of 69 cents as well as the Zacks Consensus Estimate of a loss of $1.11.
Intellia’s total revenues, comprising collaboration revenues, came in at $11.3 million for the first quarter compared with $6.4 million reported in the year-ago period. Revenues also beat the Zacks Consensus Estimate of $10.3 million.
The significant year-over-year increase in revenues was on account of revenues recorded by the company from its joint venture with AvenCell.
Shares of Intellia have plunged 57.7% in the year so far compared with the industry’s 22.7% decline.
Image Source: Zacks Investment Research
Quarter in Detail
For the reported quarter, research and development expenses were $133.1 million, up 238.9% from the year-ago figure due to increased costs for developing Intellia’s lead programs plus upfront and other payments related to the acquisition of closely-held Rewrite Therapeutics in February.
General and administrative expenses also surged 64.8% year over year to $22.4 million due to higher employee-related costs.
As of Mar 31, 2022, NTLA had cash, cash equivalents and marketable securities of $994.7 million compared with $1,086 million on Dec 31, 2021.
Pipeline Updates
Intellia is developing curative therapeutics using the CRISPR/Cas9 technology. NTLA is evaluating its lead in-vivo genome-editing candidate NTLA-2001 in a phase I study as a single-dose treatment of transthyretin (ATTR) amyloidosis. This study is evaluating NTLA-2001 in two separate arms, featuring one in ATTR amyloidosis with polyneuropathy (ATTRv-PN) patients and another in ATTR amyloidosis with cardiomyopathy (ATTR-CM) patients.
In February, Intellia reported interim data from the ATTRv-PN arm, which evaluated four different doses of NTLA-2001. ATTRv-PN patients treated with NTLA-2001 exhibited a dose-dependent reduction in serum TTR levels, achieving mean reductions of 52%, 87%, 86% and 93% at day 28 in the 0.1 mg/kg, 0.3 mg/kg, 0.7 mg/kg and 1.0 mg/kg dose cohorts, respectively.
Based on this data, NTLA decided to move forward with a fixed dose of 80mg in the part 2 portion of the phase I study. Alongside its Q1 earnings results, NTLA announced that it started dosing patients in the part 2 portion of the phase I study in the ATTRv-PN arm.
Intellia expects to present interim data from the ATTR-CM arm in second-half 2022.
NTLA-2001 is part of Intellia’s co-development and co-promotion agreement with Regeneron Pharmaceuticals (REGN - Free Report) . While NTLA is the lead party in the deal over NTLA-2001, Regeneron shares 25% of the development costs and commercial profits. Both Intellia and Regeneron are also developing therapies for hemophilia A and B.
Apart from NTLA-2001, Intellia is evaluating another pipeline candidate, NTLA-2002, in an ongoing phase I/II study for the treatment of hereditary angioedema (HAE). NTLA-2002 aims to prevent HAE attacks by suppressing plasma kallikrein activity. Interim data from the study is expected in second-half 2022.
NTLA-5001 is Intellia’s first wholly-owned ex-vivo genome editing candidate for the treatment of cancer. In March this year, NTLA announced that it dosed the first patient with NTLA-5001 in a phase I/IIa study. The study is evaluating the candidate in adults with persistent or recurrent acute myeloid leukemia (AML) who had previously received first-line therapy.
Intellia currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Alkermes (ALKS - Free Report) and Amicus Therapeutics (FOLD - Free Report) . While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, Amicus Therapeutics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of ALKS have risen 20% in the year-to-date period.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Amicus Therapeutics’ loss per share estimates for 2023 have narrowed from 19 cents to 16 cents in the past 30 days. Shares of FOLD have declined 42.7% in the year-to-date period.
Earnings of Amicus Therapeutics missed estimates in three of the last four quarters and beat the mark on one occasion, witnessing a negative surprise of 28%, on average. In the last reported quarter, Amicus Therapeutics delivered a negative earnings surprise of 107.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat
Intellia Therapeutics (NTLA - Free Report) incurred a loss of $1.96 per share for first-quarter 2022, wider than the year-ago loss of 69 cents as well as the Zacks Consensus Estimate of a loss of $1.11.
Intellia’s total revenues, comprising collaboration revenues, came in at $11.3 million for the first quarter compared with $6.4 million reported in the year-ago period. Revenues also beat the Zacks Consensus Estimate of $10.3 million.
The significant year-over-year increase in revenues was on account of revenues recorded by the company from its joint venture with AvenCell.
Shares of Intellia have plunged 57.7% in the year so far compared with the industry’s 22.7% decline.
Image Source: Zacks Investment Research
Quarter in Detail
For the reported quarter, research and development expenses were $133.1 million, up 238.9% from the year-ago figure due to increased costs for developing Intellia’s lead programs plus upfront and other payments related to the acquisition of closely-held Rewrite Therapeutics in February.
General and administrative expenses also surged 64.8% year over year to $22.4 million due to higher employee-related costs.
As of Mar 31, 2022, NTLA had cash, cash equivalents and marketable securities of $994.7 million compared with $1,086 million on Dec 31, 2021.
Pipeline Updates
Intellia is developing curative therapeutics using the CRISPR/Cas9 technology. NTLA is evaluating its lead in-vivo genome-editing candidate NTLA-2001 in a phase I study as a single-dose treatment of transthyretin (ATTR) amyloidosis. This study is evaluating NTLA-2001 in two separate arms, featuring one in ATTR amyloidosis with polyneuropathy (ATTRv-PN) patients and another in ATTR amyloidosis with cardiomyopathy (ATTR-CM) patients.
In February, Intellia reported interim data from the ATTRv-PN arm, which evaluated four different doses of NTLA-2001. ATTRv-PN patients treated with NTLA-2001 exhibited a dose-dependent reduction in serum TTR levels, achieving mean reductions of 52%, 87%, 86% and 93% at day 28 in the 0.1 mg/kg, 0.3 mg/kg, 0.7 mg/kg and 1.0 mg/kg dose cohorts, respectively.
Based on this data, NTLA decided to move forward with a fixed dose of 80mg in the part 2 portion of the phase I study. Alongside its Q1 earnings results, NTLA announced that it started dosing patients in the part 2 portion of the phase I study in the ATTRv-PN arm.
Intellia expects to present interim data from the ATTR-CM arm in second-half 2022.
NTLA-2001 is part of Intellia’s co-development and co-promotion agreement with Regeneron Pharmaceuticals (REGN - Free Report) . While NTLA is the lead party in the deal over NTLA-2001, Regeneron shares 25% of the development costs and commercial profits. Both Intellia and Regeneron are also developing therapies for hemophilia A and B.
Apart from NTLA-2001, Intellia is evaluating another pipeline candidate, NTLA-2002, in an ongoing phase I/II study for the treatment of hereditary angioedema (HAE). NTLA-2002 aims to prevent HAE attacks by suppressing plasma kallikrein activity. Interim data from the study is expected in second-half 2022.
NTLA-5001 is Intellia’s first wholly-owned ex-vivo genome editing candidate for the treatment of cancer. In March this year, NTLA announced that it dosed the first patient with NTLA-5001 in a phase I/IIa study. The study is evaluating the candidate in adults with persistent or recurrent acute myeloid leukemia (AML) who had previously received first-line therapy.
Intellia Therapeutics, Inc. Price
Intellia Therapeutics, Inc. price | Intellia Therapeutics, Inc. Quote
Zacks Rank & Stocks to Consider
Intellia currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Alkermes (ALKS - Free Report) and Amicus Therapeutics (FOLD - Free Report) . While Alkermes sports a Zacks Rank #1 (Strong Buy) at present, Amicus Therapeutics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ loss per share estimates for 2022 have narrowed from 14 cents to 3 cents in the past 30 days. Shares of ALKS have risen 20% in the year-to-date period.
Earnings of Alkermes beat estimates in each of the last four quarters, the average being 350.5%. In the last reported quarter, Alkermes delivered an earnings surprise of 1,100%.
Amicus Therapeutics’ loss per share estimates for 2023 have narrowed from 19 cents to 16 cents in the past 30 days. Shares of FOLD have declined 42.7% in the year-to-date period.
Earnings of Amicus Therapeutics missed estimates in three of the last four quarters and beat the mark on one occasion, witnessing a negative surprise of 28%, on average. In the last reported quarter, Amicus Therapeutics delivered a negative earnings surprise of 107.1%.